Free Trial

Jasper Therapeutics (JSPR) News Today

$19.10
-0.95 (-4.74%)
(As of 07/12/2024 ET)
Jasper Therapeutics logo with Medical background
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Average Recommendation of "Buy" from Analysts
Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR - Get Free Report) have received an average rating of "Buy" from the eleven research firms that are covering the stock, MarketBeat reports. Eleven equities research analysts have rated the stock with a buy rating. The average 12-month price objectiv
Jasper Therapeutics logo with Medical background
Jasper Therapeutics (NASDAQ:JSPR) Coverage Initiated at BTIG Research
BTIG Research assumed coverage on Jasper Therapeutics in a research report on Monday. They set a "buy" rating and a $90.00 price objective for the company.
Jasper Therapeutics logo with Medical background
Short Interest in Jasper Therapeutics, Inc. (NASDAQ:JSPR) Expands By 16.6%
Jasper Therapeutics, Inc. (NASDAQ:JSPR - Get Free Report) was the target of a large increase in short interest in June. As of June 15th, there was short interest totalling 798,200 shares, an increase of 16.6% from the May 31st total of 684,800 shares. Based on an average daily volume of 85,900 shares, the short-interest ratio is presently 9.3 days. Currently, 7.3% of the shares of the company are sold short.
Jasper Therapeutics logo with Medical background
Jasper Therapeutics (NASDAQ:JSPR) Earns Overweight Rating from Cantor Fitzgerald
Cantor Fitzgerald restated an "overweight" rating on shares of Jasper Therapeutics in a report on Tuesday.
Jasper Therapeutics logo with Medical background
Kingdon Capital Management L.L.C. Increases Stake in Jasper Therapeutics, Inc. (NASDAQ:JSPR)
Kingdon Capital Management L.L.C. raised its position in Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) by 16.4% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 3,540,000 shares of the company's stock after purchasing an addition
Jasper Therapeutics logo with Medical background
Opaleye Management Inc. Buys New Position in Jasper Therapeutics, Inc. (NASDAQ:JSPR)
Opaleye Management Inc. bought a new stake in Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 3,985,340 shares of the company's stock, valued at approximately $3,144,000. Jaspe
Jasper Therapeutics logo with Medical background
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Given Average Rating of "Buy" by Analysts
Jasper Therapeutics, Inc. (NASDAQ:JSPR - Get Free Report) has been assigned an average rating of "Buy" from the nine ratings firms that are currently covering the company, Marketbeat reports. Nine equities research analysts have rated the stock with a buy rating. The average 1 year target price am
Jasper Therapeutics, Inc. (NASDAQ:JSPR) COO Sells $21,744.00 in Stock
Jasper Therapeutics, Inc. (NASDAQ:JSPR - Get Free Report) COO Jeetinder Singh Mahal sold 900 shares of the business's stock in a transaction dated Wednesday, June 12th. The stock was sold at an average price of $24.16, for a total value of $21,744.00. Following the sale, the chief operating officer now directly owns 25,009 shares of the company's stock, valued at $604,217.44. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Jasper Therapeutics (NASDAQ:JSPR) Trading 0.2% Higher
Jasper Therapeutics (NASDAQ:JSPR) Stock Price Up 0.2%
Ieq Capital LLC Makes New $43,000 Investment in Jasper Therapeutics, Inc. (NASDAQ:JSPR)
Ieq Capital LLC acquired a new stake in Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 54,500 shares of the company's stock, valued at approximately $43,000. Ieq Capital LLC owned 0.49% of
Q2 2024 Earnings Forecast for Jasper Therapeutics, Inc. (NASDAQ:JSPR) Issued By HC Wainwright
Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) - Analysts at HC Wainwright lifted their Q2 2024 earnings estimates for shares of Jasper Therapeutics in a report released on Wednesday, May 15th. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings per share of (
Jasper Therapeutics (NASDAQ:JSPR) Given "Buy" Rating at HC Wainwright
HC Wainwright reaffirmed a "buy" rating and set a $65.00 price objective on shares of Jasper Therapeutics in a research report on Wednesday.
Research Analysts Offer Predictions for Jasper Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:JSPR)
Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) - William Blair issued their Q1 2025 earnings per share (EPS) estimates for shares of Jasper Therapeutics in a report issued on Tuesday, May 14th. William Blair analyst M. Phipps expects that the company will post earnings per share of ($0.91)
Monaco Asset Management SAM Takes Position in Jasper Therapeutics, Inc. (NASDAQ:JSPR)
Monaco Asset Management SAM purchased a new stake in shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 249,563 shares of the company's stock, valued at appr
Jasper Therapeutics (NASDAQ:JSPR) Earns Buy Rating from Analysts at HC Wainwright
HC Wainwright assumed coverage on shares of Jasper Therapeutics in a research report on Monday. They set a "buy" rating and a $65.00 price target on the stock.
Jasper Therapeutics Inc Ordinary Shares
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Position Raised by Fernwood Investment Management LLC
Fernwood Investment Management LLC increased its position in shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) by 8.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor own
Jasper Therapeutics (NASDAQ:JSPR) Research Coverage Started at Evercore ISI
Evercore ISI assumed coverage on Jasper Therapeutics in a research report on Wednesday. They set an "outperform" rating and a $65.00 price objective on the stock.
Jasper Therapeutics (NASDAQ:JSPR) Receives New Coverage from Analysts at Royal Bank of Canada
Royal Bank of Canada began coverage on shares of Jasper Therapeutics in a report on Thursday. They set an "outperform" rating and a $70.00 price target for the company.
Jasper Therapeutics (NASDAQ:JSPR) Earns Outperform Rating from Analysts at TD Cowen
TD Cowen assumed coverage on shares of Jasper Therapeutics in a research report on Monday. They issued an "outperform" rating for the company.
JSPR Jul 2024 40.000 call
Get Jasper Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for JSPR and its competitors with MarketBeat's FREE daily newsletter.

Anyone can do this, rich and poor alike (Ad)

I’ve been a financial analyst for almost three decades, but I don’t think I’ve ever seen anything quite like this before.

Watch now

JSPR Media Mentions By Week

JSPR Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

JSPR
News Sentiment

0.74

0.91

Average
Medical
News Sentiment

JSPR News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

JSPR Articles
This Week

7

2

JSPR Articles
Average Week

Get Jasper Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for JSPR and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:JSPR) was last updated on 7/14/2024 by MarketBeat.com Staff

From Our Partners